TSI'S REVENUES RISE, LOSS DECLINESTSI Corp. (NASDAQ:TSIN) of Worcester, Mass., anticipatesanother increase in revenues this spring after TSI RedfieldLaboratories, acquired last November, becomes operational.

"The rapid growth in revenues in the three- and six-monthperiods reflects the growth of the TSI Mason ResearchInstitute, as well as the successful acquisitions of TSIWashington Laboratories and, more recently, of the TSI Centerfor Diagnostic Products," said James Sherblom, TSI's chairmanand chief executive officer.

Second quarter ended Dec. 31(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $3,855 1,552 +148Operating income (loss) (359) (671) +46Net income (loss) (532) (722) +26Net income per share (loss) (.06) (.12) +50Outstanding shares 9,017 6,149 +47

HANA'S LOSS DEEPENS

Hana Biologics Inc. (NASDAQ:HANA) of Alameda, Calif., said thata $3.1 million loss in the recently ended six-month periodreflected an increase in research and developmentexpenditures. A decline in revenues to $1.7 million during theperiod resulted from comparison to a year-ago period whenHana divested certain product lines.

The company recorded a $12.8 million gain in the last fiscalyear on the sale of the product lines and a $1.6 million expenseas a result of a reorganization last quarter.

Second quarter ended Dec. 30(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $838 858 -2Net income (loss) (1,552) (1,162) -34Net income per share (loss) (.23) (.17) -35Outstanding shares 6,721 6,675 negl.

SYNERGEN'S REVENUES FALL, LOSS DEEPENS

Synergen Inc. (NASDAQ:SYGN) of Boulder, Colo., said it expectsits operating results to fluctuate significantly from quarter toquarter, primarily due to the timing of revenues received frompartners.

By the end of 1990, "we had advanced three proprietaryproducts into clinical trials for five medical indications," saidKenneth J. Collins, Synergen's vice president of finance.Trofaktm is in advanced clinical trials for treating chronic skinulcers. IL-1ra is being evaluated as a treatment for rheumatoidarthritis and septic shock, and SLPI is being tested at theNational Institutes of Health in patients with cystic fibrosis andgenetic emphysema.

Expenses for the year are consistent with projections andreflect the company's efforts to commercialize these products,he said.

Fourth quarter ended Dec. 31(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $1,937 4,467 -57Net income (loss) (3,823) (846) -352Net income per share (loss) (.36) (.10) -260Outstanding shares 10,685 8,818 +21

Year ended Dec. 31(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $12,746 14,796 -17Net income (loss) (6,412) (1,311) -389Net income per share (loss) (.62) (.15) -76Outstanding shares 10,269 8,766 +17

MYCOGEN'S REVENUES INCREASE, LOSS DEEPENS

Mycogen Corp. (NASDAQ:MYCO) of San Diego said fourth-quarter results include a loss on investments of $2.6 million or26 cents per share and a special charge of $574,000 or 6 centsper share.

The loss on investments reflects the write-down of Mycogen'sinterest in Safer Inc. as a result of the sale last month of thecompany to a third party, the company said. "The sale of Saferrelates to the retail business and has no impact of thecommercial rights to products acquired by Mycogen earlier inthe year," said Jerry Caulder, Mycogen's chairman.

Fourth-quarter and year-end results also reflect the company'sdecision to step up commercial development activities, thecompany said. Mycogen said that in response to competitivepressures in certain markets, the company has implementedprograms to reduce inventory and accelerate the adoption ofbiopesticides by farmers, which resulted in a special charge toinventory.

Fourth quarter ended Dec. 31(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $3,525 2,510 +40Net income (loss) (3,886) (258) -1,400Net income per share (loss) (.33) (.03) -1,000Outstanding shares 11,701 8,188 +43

Year ended Dec. 31(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $14,980 9,085 +65Net income (loss) (4,492) (1,880) -139Net income per share (loss) (.44) (.26) -69Outstanding shares 10,323 7,184 +44

(c) 1997 American Health Consultants. All rights reserved.

No Comments